Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTX siPDL1

Next Previous
X
Search
Drug Profile

TTX siPDL1

Alternative Names: Magnetic nanocarrier-conjugated siRNA against PDL1 - TransCode Therapeutics; Magnetic nanocarrier-conjugated small interfering RNA against programmed death ligand 1 - TransCode Therapeutics; TTX-siPDL1

Latest Information Update: 15 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TransCode Therapeutics
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action B7-H1 antigen expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pancreatic cancer; Solid tumours

Most Recent Events

  • 09 Nov 2022 Pharmacodynamics data from a preclinical trial in Pancreatic cancer released by TransCode Therapeutics
  • 11 Aug 2022 Preclinical trials in Pancreatic cancer in USA (Parenteral) (Transcode therapeutics pipeline, August 2022)
  • 14 Jun 2022 TTX siPDL1 receives Orphan Drug status for Pancreatic cancer in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top